Abbvie Stock News

Five Oceans Advisors acquired a new position in AbbVie Inc. (NYSE:ABBV) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,894 shares of the companys stock, valued at approximately $312,000. Several other institutional investors have also bought and sold shares []

AbbVie to Present at the Piper Sandler Healthcare Conference AbbVie (NYSE: ABBV)

AbbVie (NYSE:ABBV) was upgraded by analysts at Societe Generale from a hold rating to a buy rating in a research report issued on Tuesday, The Fly reports. Other research analysts also recently issued research reports about the stock. Truist began coverage on shares of AbbVie in a research report on Tuesday, July 27th. They issued []

Publishers Immunology market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic

Artificial tears, also known as Hyaluronic Acid Eye Drops Market, are used to relieve eye irritation and dryness. Sodium hyaluronate eye drops are widely recommended for smoothing, moistening, and lubricating the eye surface. Dry eye syndrome is treated with hyaluronate,

Related Stocks: ABBV , CDNS , SYK , ALL , BIIB , VNQ , BA , ALLE ,

Hikari Power Ltd lifted its stake in AbbVie Inc. (NYSE:ABBV) by 13.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 48,963 shares of the companys stock after purchasing an additional 5,850 shares during the quarter. Hikari Power Ltds holdings in AbbVie were worth []

IFM Investors Pty Ltd increased its stake in AbbVie Inc. (NYSE:ABBV) by 0.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 235,869 shares of the companys stock after purchasing an additional 173 shares during the period. IFM Investors Pty Ltds holdings []

Key Companies in Breast Implants Market are Sientra, Inc. (California, U.S.) , GC Aesthetics (Dublin, Ireland) , POLYTECH Health & Aesthetics GmbH (Dieburg, Germany) , AbbVie Inc. (Illinois, U.S.) , Mentor Worldwide LLC (California, U.S.) , CEREPLAS (Cambrai, France) , Establishment Labs S.A. (Alajuela, Costa Rica) , LABORATOIRES ARION (Sophia Antipolis, France) , Other Players Key Companies in Breast Implants Market are Sientra, Inc. (California, U.S.) , GC Aesthetics (Dublin, Ireland) , POLYTECH Health & Aesthetics GmbH (Dieburg, Germany) , AbbVie Inc. (Illinois, U.S.) , Mentor Worldwide LLC (California, U.S.) , CEREPLAS (Cambrai, France) , Establishment Labs S.A. (Alajuela, Costa Rica) , LABORATOIRES ARION (Sophia Antipolis, France) , Other Players

The biopharma industry has high ambitions to improve therapies for patients across many disease categories, drawing on a wealth of technological advances that have been emerging and maturing in recent years. Even after the mass mobilization against COVID-19, it is

Stonnington Group LLC decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,013 shares of the companys stock after selling 513 shares during the quarter. Stonnington Group LLCs holdings []

Piscataqua Savings Bank reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,767 shares of the companys stock after selling 214 shares during the quarter. AbbVie comprises 1.2% of Piscataqua Savings Banks []

Lenox Wealth Advisors LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 40.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,239 shares of the companys stock after purchasing an additional 354 shares during the quarter. Lenox Wealth Advisors LLCs holdings in AbbVie were worth $134,000 as of its most []